Ginkgo expects to meet 2022 total revenue guidance of $460-480M; cash ~$1.3B

Ginkgo Bioworks Holdings, Inc.

2022-FY EPS reported -$1.25 revenue$477,706,000

Expects 55-60 new Cell Programs added in 2022, nearly doubling 2021 additions.
Foundry revenue expected below $150-170M guidance; Biosecurity revenue exceeds $310M.
Ended 2022 with approx. $1.3B cash; strong liquidity despite challenging macro.
Opened Bioworks7 (6,600 sq ft BSL-2 lab) for mammalian cell engineering; launched Ginkgo Enzyme Services.
Full audited Q4 and FY 2022 results due March 2023; 2023 outlook to be provided then.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Ginkgo Bioworks Holdings, Inc. reported the year ended December 31, 2022 results: revenue $460 – 480 million. Guidance reaffirmed.

Period: the year ended December 31, 2022
Revenue: $460 – 480 million
Guidance: reaffirmed
Result: preliminary results

Exact text from the filing

Key Performance Highlights • Ginkgo reiterated its expectations of 55-60 new Cell Programs added to the Foundry platform in 2022 • Ginkgo continues to expect Total revenue of $460 – 480 million in 2022 o Preliminary unaudited Foundry revenue is expected to be below the previously disclosed guidance of $150 – $170 million in 2022 due to a subset of targeted

View on SEC.gov

44 earnings releases filed in the last 30 days. Browse all earnings releases →

Ginkgo Bioworks Holdings, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-23-000640

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.